Effects of Processing and Storage Conditions on Amyloid Beta (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice
Overview
Authors
Affiliations
Background: Reported concentrations of amyloid beta (1-42) (A beta 42) and tau in cerebrospinal fluid (CSF) differ among reports. We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of A beta 42 and tau in CSF.
Methods: Stability of samples stored at -80 degrees C was determined by use of an accelerated stability testing protocol according to the Arrhenius equation. A beta 42 and tau concentrations were measured in CSF samples stored at 4, 18, 37, and -80 degrees C. Relative CSF concentrations (%) of the biomarkers after one freeze/thaw cycle were compared with those after two, three, four, five, and six freeze/thaw cycles. In addition, relative A beta 42 and tau concentrations in samples not centrifuged were compared with samples centrifuged after 1, 4, 48, and 72 h.
Results: A beta 42 and tau concentrations were stable in CSF when stored for a long period at -80 degrees C. CSF A beta 42 decreased by 20% during the first 2 days at 4, 18, and 37 degrees C compared with -80 degrees C. CSF tau decreased after storage for 12 days at 37 degrees C. After three freeze/thaw cycles, CSF A beta 42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. Centrifugation did not influence the biomarker concentrations.
Conclusions: Repeated freeze/thaw cycles and storage at 4, 18, and 37 degrees C influence the quantitative result of the A beta 42 test. Preferably, samples should be stored at -80 degrees C immediately after collection.
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.
Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.
PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.
Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.
Pils M, Dybala A, Schaffrath A, Rehn F, Kutzsche J, Blomeke L Alzheimers Res Ther. 2024; 16(1):223.
PMID: 39402637 PMC: 11472473. DOI: 10.1186/s13195-024-01597-3.
Botter S, Kessler T Int J Mol Sci. 2023; 24(18).
PMID: 37762582 PMC: 10531693. DOI: 10.3390/ijms241814281.
Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.
Hu W, Nayyar A, Kaluzova M Neurotherapeutics. 2023; 20(4):955-974.
PMID: 37378862 PMC: 10457281. DOI: 10.1007/s13311-023-01370-8.
Pils M, Dybala A, Rehn F, Blomeke L, Bujnicki T, Kraemer-Schulien V Diagnostics (Basel). 2023; 13(10).
PMID: 37238187 PMC: 10217173. DOI: 10.3390/diagnostics13101702.